Not for release or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction where such release or distribution would be unlawful. Please see the important notice at the end of this announcement.

‍

Berlin, June 20, 2023 – Green Karat, a renowned Canadian company that specializes in the cultivation of Craft Cannabis, proudly announces its expansion into the European market. In collaboration with Cantourage Group SE (hereinafter “Cantourage,” ISIN: DE000A3DSV01), a leading European company for the production and distribution of cannabis-based medicinal products, Green Karat will soon make its high-quality cannabis flowers available to the German market. This expansion means a further improvement in the supply of high-quality craft cannabis for patients in Germany, who can already obtain medicinal cannabis as a prescription drug through pharmacies.

‍

Green Karat is based in the province of Québec, Canada, and operates a state-of-the-art production facility of 1,160 square meters on the picturesque north coast of Montreal. With four specially equipped flower rooms and an annual cultivation capacity of 1,500 kg, Green Karat is ideally positioned for the cultivation of Craft Cannabis. Run by family and friends, the business is operated by a small but highly skilled team with many years of experience. Green Karat places great emphasis on growing small batches of premium cannabis flowers to ensure outstanding quality. The company is looking forward to entering into other international markets soon.

‍

Kim Supple, Quality Manager of Green Karat, expressed her excitement about the new partnership: “Working with Cantourage will allow us to reach another milestone in the development of our company: entering the European market. We are proud to be able to provide patients in Germany with our unique cultivars. In doing so, we of course remain committed to our unwavering dedication to quality.”

‍

“With Green Karat, we have gained an important partner whose products are already highly regarded in Canada. Collaborations of exactly this nature allow us to provide patients in this country with premium cannabis from the pharmacy,” commented Bernhard Retzer, Cantourage’s Global Director of Sales.

‍

About Green Karat
Green Karat has been one of Health Canada’s licensed cannabis producers since May 2020. Founded on Montreal’s north shore, the family-owned business is dedicated to cultivating high-quality, handcrafted cannabis. In addition to motivation and dedication, it is the company’s unwavering determination that drives it to excel. Green Karat is aware of its social responsibility and its commitment to Health Canada. As such, the cultivation company always maintains the highest standards in the industry as set by Health Canada. The result of these constant efforts are small batches of certified premium cannabis.

‍

About Cantourage
Cantourage is a leading European producer and distributor of cannabis-based medicinal preparations and drugs. The Berlin-based company was founded in 2018 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to become part of the growing European medical cannabis market faster, easier and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In this context, Cantourage ensures compliance with the highest European pharmaceutical quality standards at all times. The company offers pharmaceutical-grade products in all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on November 11, 2022 and is listed under ticker symbol “HIGH”.

More information: www.cantourage.com

‍

This announcement does not constitute a public offer or an advertisement for a public offer in the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).
This announcement is not an offer of securities for sale in the United States of America. Securities may not be sold or offered in the United States of America absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”). Any public offering of securities to be made in the United States would be made by means of a prospectus that could be obtained from the Company. This prospectus would contain detailed information about the Company and its management, as well as the Company’s financial information. There will be no public offering of the securities referred to in this announcement in the United States of America.
In the United Kingdom, this information may only be communicated to and is only directed at (i) professional investors in the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), or (ii) high net worth companies falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to herein as “Relevant Persons”). The Securities are only available to Relevant Persons and any invitation, offer or agreement to subscribe for, purchase or otherwise acquire such Securities will only be engaged in with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this announcement or any of its contents.
Subject to certain exceptions, the securities referred to in this announcement may not be sold or offered in Australia, Canada or Japan, or to or for the account or benefit of any national, resident or citizen of Australia, Canada or Japan.

‍

Press contact Cantourage:
Frederick Steudemann
M +49 (0)30 4701 350-50
pr@cantourage.com